<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; issue. of</title>
	<atom:link href="http://www.tapanray.in/tag/issue-of/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Unlike China, IPR issues in India are being hijacked by the issue of ‘Access to Affordable Modern Medicines’.</title>
		<link>http://www.tapanray.in/unlike-china-ipr-issues-in-india-are-being-hijacked-by-the-issue-of-access-to-affordable-modern-medicines/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unlike-china-ipr-issues-in-india-are-being-hijacked-by-the-issue-of-access-to-affordable-modern-medicines</link>
		<comments>http://www.tapanray.in/unlike-china-ipr-issues-in-india-are-being-hijacked-by-the-issue-of-access-to-affordable-modern-medicines/#comments</comments>
		<pubDate>Sun, 19 Apr 2009 07:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[are]]></category>
		<category><![CDATA[Being]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[hijacked]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue. of]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Modern]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Unlike]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=912</guid>
		<description><![CDATA[‘Incremental innovation’, related to the pharmaceutical industry, has become a point of raging debate in India. Over a period of time ‘not really a breakthrough’ but ‘incremental inventive steps’ to discover New Chemical Entities (NCE), which would offer significant benefits &#8230; <a href="http://www.tapanray.in/unlike-china-ipr-issues-in-india-are-being-hijacked-by-the-issue-of-access-to-affordable-modern-medicines/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unlike-china-ipr-issues-in-india-are-being-hijacked-by-the-issue-of-access-to-affordable-modern-medicines/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
